Zarumin

---

Zarumin was a medication trademarked in 1954 by Pharmaceuticals, Inc. of Newark, New Jersey, the makers of Geritol, and was filed under the category of leather products. Its trademark expired on 5/14/1987, and was never renewed afterwards.

Zarumin was prepared to combat pain from arthritis and rheumatism. It was one of many amphetamine and amphetamine-laced medications which were once widely advertised and sold over-the-counter in the United States, without prescription, which were later subject to government restriction, partial bans, or selective criminalization.

Legal status

In 1971 the Convention on Psychotropic Substances held in the United Nations it was decided that amphetamine would be classified as a schedule II controlled substance in all 183 state parties. This is thought to be the reason that the patent for Zarumin was never renewed, as its base component was no longer legal.

Reasons for ban

Very high doses of amphetamine can result in psychosis (e.g., delusions and paranoia) which rarely occurs at therapeutic doses even during long-term use. Recreational doses are generally much larger than prescribed therapeutic doses and carry a far greater risk of serious side effects. This led to the ban of Amphetamine, and effectively the ban of Zarumin.

References

This article "Zarumin" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:Zarumin. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.

📰 Article(s) of the same category(ies)

• Global Newborn Society
• EDEN cohort study
• Jerome Quezel-Guerraz
• Professor Dr. Martin Gangnon
• Hossein Goudarzi
• Michael Zimpfer
• PrivateGP

---